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The pathogen 
• Mycoplasma mycoides subsp. mycoides (Mmm) “SC” 
• Class of Mollicutes 
•cell wall 
•2 genomes fully sequenced 
•PG1 and Gladysdale 
• 1,211 kb 
•NGS based phylogeny 
•Molecular dating (Dupuy et al  2012) 
   
 contagious bovine pleuropneumonia (CBPP) 
 Africa 
 lymphatics / lungs  
The disease 
- chronic CBPP 
- sequestrum 
- long term persistance 
- and excretion ? 
- acute CBPP (15-30%) 
- massive inflammation of lungs 
- hepatisation 
- pleurisy  
Need for improved Vaccines 
Advantages 
Relatively low production costs 
Very long conservation at -20°C once freeze-dried 
Easy administration (sub-cutaneous) 
T1sr: completely safe 
Transient sero-conversion (allows detection of outbreaks) 
Repeated vaccinations result in good protection 
 
Drawbacks 
Thermolability (freeze-dried or reconstituted) 
Freeze-drying needs industrial skill 
T1/44: some residual virulence (primo-vaccination) 
Lack of sero-conversion does not allow sero-monitoring  
of vaccination campaigns 
A single administration does not yield  good  protection 
Protection is short-lived (T1sr: 6 months, T1/44: one year) 
Eradication cannot be achieved with vaccination alone 
Currently: Live,  empirically attenuated strains injected sub-cutaneously 
Willems reaction 
With T1/44 (not T1sr) 
In animals vaccinated for the first time 
Appears 10-20 days post vaccination 
0 to 5 % of vaccinees 
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Innate immunity                                                                                                           
•  during primary infection (injection subcut/intubetion/contact) 
Lesions in lungs and locally (subcut) are typical of inflammation. Less severe 
when injection at the tip of the tail importance of the lymphatic system 
TNF-α is produced in alveolar macrophages in response to both pathogenic 
and non pathogenic MmmSC (in vitro)                                                                 
(Jungi T et al. Microbial pathogenesis 1996) 
Archetypal inflammatory cytokines (pro and anti) are detected early in the plasma 
and at higher levels in acute cbpp (n=4). No effect of CD4+T cells depletion.                                                                                                         
(Sacchini F et al. BMC Vet Res 2012)  
Summary: 
No endotoxins/ Mechanisms of inflammation (chimiokines)?  
Very little data on MmmSC-host cells interactions/ role of epithelial lung cells? 
Which cell types are producing proinflammatory cytokines ? 
 
presence of myeloid cells (ilA24) in lesions.                                                                                                                     
(Jores J et al.Vet Immunol Immunopathol 2008) 
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Humoral immunity                                                                                                          1/2 
•  during primary infection (contact challenge/intubation) 
Lesions size correlates with MmmSC-specific IgM titers in serum (CFT, 
agglutination) 
IgG titers to 35 out of 65 recombinant surface proteins monitored (luminex) in 5 
cattle (Hamsten C et al. Clin Vaccine Immunol. 2010) 
higher early anti-MmmSC IgG1and G2 titers (ELISA) in severe cbpp after 
intubation (n=4) (Sacchini F et al. BMC vet res 2012) 
Detection of MmmSC-specific IgA  in serum and bronchoalveaolar fluids 
(ELISA) of animals with less severe disease (n=5)  / detectable for only 1-3 
months in serum   (Niang M et al. Vet Res. 2006) 
Summary; 
Possible role of immune complexes (IgM, IgG1, IgG2) in the pathology and IgA in protection  
Proteins targetted?  potential of luminex approach with individual surface proteins 
•  during vaccination (T144/T1sr) 
Humoral immunity                                                                                                          2/2 
Weak antibody titers (CFT, cELISA) and most animals are negative after 3 
months. No correlation with protection after contact challenge              
(Thiaucourt F, et al. Ann. N Y Acad Sci 2000) 
Strong IgG titers against 4 out of 65 recombinant surface proteins (luminex) with 
LppQ as potential indicator of protection after contact challenge (n=5)              
(Hamsten C et al. Clin Vaccine Immunol. 2010) 
•  during primary infection (contact challenge/intubation) 
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Summary: 
Potential of the luminex methodology to identify markers of vaccine success before challenge 
Cell mediated immunity (CMI)                                                                                           1/3 
Sustained MmmSC-specific recall activation of CD4+T lymphocytes                   
and IFN-γ production is associated with a better control of cbpp                                        
(Dedieu L et al. Vet Immunol Immunopathol 2005) 
No correlation between MmmSC-specific recall IFN-γ production and protection after 
intubation. No build up of T-lymphocytes in lung lesions but presence of myeloid 
cells.                                                                                                                     
(Jores J et al. Vet Immunol Immunopathol 2008) 
•  during primary infection (contact/intubation challenge) / peripheral blood 
Depletion studies indicate that removal of CD4+T lymphocytes has no incidence on 
disease progression (Sacchini F et al. Vet Res 2011)  
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Summary: 
No role for CD4 in primary infection  
 
Cell mediated immunity (CMI)                                                                                           2/3 
•  after recovery (fibrotic scars) / draining lymph nodes 
MmmSC-specific recall activation of CD4+T lymphocytes but no proliferation 
(n=5) (Dedieu L et al. Vet Res 2006) 
MmmSC-specific recall proliferation of B and CD4+T lymphocytes / strictly CD4-
dependent / CD4 express memory markers, produce IFN-γ but no IL-4 (Th1 or Th17?)                                         
(Totté et al. Vet Res 2008) 
MmmSC-specific memory CD4 comprise Tem (short lived) and Tcm (long lived)        
(Totté et al. Dev Comp Immunol 2010)  
•  during primary infection (contact/intubation challenge) / peripheral blood 
memory + protection  
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Summary: 
Strong CD4 memory response after recovery  role in protection against secondary challenge ? 
Potential of CD4+Tcm as markers of protection as in bovine tuberculosis 
 
Effector memory (Tem) vs central memory (Tcm) 
Tem 
blood-tissues-lymph circulation (ccr5, cxcl3) 
low proliferation  
strong IFN-γ response 
Months after infection/immunisation 
 
Tcm 
blood-lymph circulation (cd62l, ccr7) 
high proliferation  
low IFN-γ response 
years after infection/immunisation 
 differentiate into T effectors upon Ag encounter 
 
local response to 
 challenge 
but short-lived 
Long-lived pool  
of effectors  
improved vaccines            Tem + Tcm 
Strong challenge 
long term immunity 
Cell mediated immunity (CMI)                                                                                           3/3 
•  after recovery (fibrotic scars) / draining lymph nodes 
MmmSC-specific recall IFN-γ and proliferation of CD4+Tem and Tcm but only after 3 
shots of T1 vaccine (n=5) / lower Tcm response in comparison to animals that 
recovered from CBPP                                                                                                        
(Totté P et al. PloS One 2013)== 
•  during primary infection (contact/intubation challenge) / peripheral blood 
Immunological memory  
•  after vaccination (T144/T1sr) / peripheral blood 
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no recall activation of lymphocytes in cattle vaccinated 2 months previously in the tail 
tip with a single dose of the T1 vaccine                                                               
(Roberts DH, et al. Infect Immun  1973) 
Summary: 
Low T-cell immunogenicity of T1 vaccines  
Immunoinhibitory mechanisms? 
 
Immunology of CBPP: opportunities from the 
CBPP BEN1 vaccine project  
  confirm in larger animal groups data obtained previously  
IgG1, IgG2 and IgA responses against individual or groups of specific antigens as 
indicators of protection/pathology (ILRI)  
Correlation between higher production of inflammatory cytokines early after 
challenge and disease severity (?)   
 
Poor T-cell immunogenicity induced by live vaccines (ILRI)  
 
Immunology of CBPP: opportunities from the 
CBPP BEN1 vaccine project  
  improve our current understanding of cbpp immunology  
Involvement of various T-cells sub-types (Th orientation) in vaccinated animals 
undergoing challenge  (ILRI+CIRAD) 
characterize global immune responses and cell types involved in the pathology      
(HVRI+CIRAD)    
characterize global immune protective mechanisms induced by attenuated CBPP 
vaccines (CIRAD+ILRI) 
Characterize the role of EBL in innate immune responses to MmmSC infection (HVRI) 
Immunology of CBPP: opportunities from the 
CBPP BEN1 vaccine project  
 definition of markers that can predict vaccine efficacy after vaccination but before challenge 
      (CIRAD+ILRI) 
Lessons from the bovine tuberculosis model (20 years of research on CMI in 
cattle and 10 years on correlates of protection) 
 whole blood and T-cell based assays (recall IFN-γ response) are good markers of                   
protection at group level but NOT at individual level 
 IFN-γ cultured ELISPOT (Tcm) and intracellular INF-γ labeling in stimulated CD4 are 
good correlates of protection at individual level (R2=0.79 to 0.83) but complex and time 
consuming                                                                                                                    
(Hope JC et al. Clin Vaccine Immunol  2011)                                              
 whole bovine genome transcriptomics has identified a 3-genes signature (il-22, ifn-
γ, mt3) that can predict protection following vaccination (14 weeks) and before 
challenge   confirmed by rt-qPCR in independent experiment (n=16)                          
(Bhuju S et al. PLoS Pathog. 2012) 
Thank you for your attention 
